论文部分内容阅读
目的 探讨DNA拓扑异构酶 (TopoII)与人脑胶质瘤的发病年龄、性别 ,肿瘤大小、病理分型、恶性程度、复发及多药耐药的关系。方法 应用流式细胞术对 30例新鲜胶质瘤组织及 5例正常脑组织中DNATopoII的表达进行对照研究。结果 5例正常脑组织中TopoII低水平表达。TopoII在不同性别 ,年龄、肿瘤大小之间的阳性表达率无明显差异 (P >0 0 5) ;低度恶性组与中高度恶性组TopoII阳性细胞百分率分别为 ( 19 35%± 18 2 1% )和 ( 45 92 %± 15 11% ) ,差异有显著性意义 (P <0 0 5) ,而中度恶性和高度恶性组间差异无显著性意义 (P >0 0 5) ;6例原发性胶质瘤与 5例复发性胶质瘤中TopoII阳性细胞百分率分别为 ( 56 96 %± 14 92 % )和( 2 7 6 9%± 17 75% ) ,差异有显著性意义 (P <0 0 5)。DNA拓扑异构酶II的表达量随胶质瘤的恶性程度增加而升高 ,复发性胶质瘤的DNATopoII表达量下降。结论 TopoII与胶质瘤的生物学特性相关 ,可作为恶性程度较客观的指标 ;TopoII催化反应活性的降低或(和 )数量的减少是肿瘤多药耐药的重要机制之一
Objective To investigate the relationship between DNA topoisomerase (TopoII) and the age, sex, tumor size, pathological type, malignancy, relapse and multidrug resistance in human gliomas. Methods Flow cytometry was used to compare the expression of DNATopoII in 30 cases of fresh glioma and 5 cases of normal brain tissue. Results In 5 normal brain tissues, TopoII was expressed at a low level. The positive rates of TopoII in different gender, age and tumor size had no significant difference (P> 0.05). The percentage of TopoII positive cells in the low malignant group and the high-grade malignant group was (19 35% ± 18 21% ) And (45 92% ± 15 11%), respectively. There was no significant difference between the moderately malignant and the highly malignant group (P> 0.05) The percentage of TopoII positive cells in gliomas and recurrent gliomas were (56 96% ± 14 92%) and (27 6 9% ± 17 75%), respectively, with significant difference (P < 0 0 5). The expression of DNA topoisomerase II increased with the malignant degree of glioma, and the expression of DNATopoII in recurrent glioma decreased. Conclusion TopoII is associated with the biological characteristics of gliomas and may be used as an objective indicator of malignancy. The reduction of (or) the activity of TopoII is one of the important mechanisms of multidrug resistance in tumors